Handelsavisen
prelaunch
Companies ›Healthcare ›4570.T
45
4570.T — Tokyo Stock Exchange Pharmaceuticals

4570.T

¥940,00
Open in Charts → Attach watcher ⌖
— —
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
8,8B JPY
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
21,6 %
ROE
16,4 %
Net margin
25,7 %
Debt / equity
0,13
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
16,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4570.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4570.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 4.94 and cash and equivalents amounting to 825,731,000 JPY. Its debt-to-equity ratio is 0.13, indicating a conservative capital structure with limited leverage. The price-to-book ratio of 6.85 and price-to-tangible-book ratio of 6.85 suggest that the company is trading at a premium to its book value. The enterprise value to EBITDA ratio of 46.55 and enterprise value to revenue ratio of 10.05 reflect a high valuation relative to earnings and revenue.

    The company's profitability is robust, with a return on equity of 16.45% and a return on assets of 13.5%. Its operating margin is 21.6%, and net margin is 25.7%, both of which are strong indicators of efficient operations and pricing power. These metrics align with the industry's preferred focus on profitability and returns, as outlined in the industry_config.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks. The company's revenue concentration is high, with no clear indication of multiple revenue streams or geographic markets.

    The company's growth trajectory is stable, with a revenue of 969,530,000 JPY and a net income of 249,046,000 JPY. The company's capital expenditure of -59,660,000 JPY indicates a reduction in investment in physical assets, which may signal a focus on cost optimization or a mature business model. The company's free cash flow of 204,813,000 JPY supports its ability to fund operations and return value to shareholders.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's dilution potential is low, and no adjustments have been applied to its valuation metrics. The company's conservative capital structure and strong liquidity position contribute to its low risk profile.

    Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's last actual EPS was 26.74 JPY, and its last actual revenue was 969,530,000 JPY. These figures align with the company's reported financial performance and suggest consistent earnings and revenue generation.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 4.94 and significant cash reserves.
    • The company's profitability is robust, with a return on equity of 16.45% and a return on assets of 13.5%.
    • The company's revenue is concentrated in a single business segment, which may increase its exposure to regional or sector-specific risks.
    • The company's valuation metrics, including a price-to-book ratio of 6.85 and an enterprise value to EBITDA ratio of 46.55, suggest a premium valuation.
    • The company's risk profile is low, with no immediate liquidity or dilution flags detected.
    • The company's capital expenditure is negative, indicating a reduction in investment in physical assets.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥940,00
    Market cap
    ¥10.37B
    Enterprise valueⓘ
    ¥9.74B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    53.1x
    P / Bⓘ
    6.8x
    P / Tangible bookⓘ
    6.8x
    Tangible book
    ¥1.51B
    Net cashⓘ
    ¥621.5M
    Current ratioⓘ
    4.9
    Debt / equityⓘ
    0.1
    ROAⓘ
    13.5%
    ROEⓘ
    16.4%
    Cash conversionⓘ
    74.0%
    CapEx / revenueⓘ
    -6.2%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin21,6 %Above P75
    Net Margin25,7 %Best in class
    ROE16,4 %Above P75
    Capex / Rev-6,2 %Below median
    D/E0,13Above median
    Cash Conv0,74Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 4570.T Market data — financials · 2026-05-26
    • Immuno-Biological Laboratories Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4570.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage